Status:
Concluded with an LOI
Manufacturer:
Merck Canada Inc.
Indication:
Renal cell carcinoma (RCC), for adjuvant treatment of adult patients, at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions
Last updated December 15, 2022
Status:
Concluded without agreement
Manufacturer:
Alexion Pharma Canada Corp.
Indication:
Myasthenia Gravis
Last updated December 12, 2022
Status:
Concluded without agreement
Manufacturer:
Alexion Pharma Canada Corp.
Indication:
Neuromyelitis optica spectrum disorder (NMOSD)
Last updated December 12, 2022
Status:
Concluded with an LOI
Manufacturer:
UCB Canada Inc.
Indication:
Psoriasis, moderate to severe plaque
Last updated December 9, 2022
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Growth hormone deficiency
Last updated November 28, 2022
Status:
Concluded with an LOI
Manufacturer:
Seagen Canada Inc.
Indication:
Unresectable, locally advanced or metastatic urothelial cancer in adult patients who have previously received a platinum-containing chemotherapy and programmed death receptor-1 or programmed death-ligand 1 inhibitor therapy
Last updated November 28, 2022
Status:
Concluded with an LOI
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Migraine, prevention
Last updated November 22, 2022
Status:
Negotiations were not pursued
Manufacturer:
Biogen Canada Inc.
Indication:
Spinal Muscular Atrophy in adult patients over 18 years of age
Last updated November 14, 2022
Status:
Concluded with an LOI
Manufacturer:
BGP Pharma ULC, d.b.a. Viatris Canada
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated November 14, 2022
Status:
Concluded with an LOI
Manufacturer:
Pendopharm, a division of Pharmascience Inc.
Indication:
Mild to moderate essential hypertension and management of chronic stable angina
Last updated November 14, 2022